Prolight Diagnostics
Prolight Diagnostics AB is a Swedish pre-commercial medical diagnostics company developing the Psyros® digital point-of-care platform, which uses proprietary single molecule counting to deliver ultra-sensitive biomarker results from a drop of blood in under 10 minutes for emergency and acute care settings.
- Company typePrivate
- Founded1999
- HeadquartersLund, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prolight Diagnostics does
Prolight Diagnostics AB is a privately held Swedish medical diagnostics company founded in 1999 and headquartered in Lund, Sweden. The company develops patient-near analysis (PNA) / point-of-care (POC) diagnostic systems intended to deliver laboratory-quality results outside traditional hospital laboratories. Its target end users are emergency departments, ambulances, healthcare centers, and nursing homes that require rapid diagnostic results for time-critical conditions, with the initial commercial focus on acute heart attack detection via high-sensitivity troponin measurement.
The company's core product is the Psyros® platform, a digital POC instrument built on proprietary single molecule counting technology. The method uses thresholding to determine whether the signal from each molecule is on or off, eliminating background noise and enabling measurement of ultra-low biomarker concentrations from a single drop of blood, with results delivered in 10 minutes or less. The platform supports multiplex testing for multiple biomarkers simultaneously and is being designed for reliable operation in demanding clinical environments such as ambulances and emergency departments. A secondary product, MicroFlex, extends the POC portfolio with disposable test cards for in-vitro diagnostic testing. Psyros® achieved formal design freeze in April 2026 with manufacturing partner G&H | ITL and is progressing into pilot unit production.
Prolight operates in a pre-commercial stage and has not disclosed revenue. The planned business model centers on direct enterprise sales of small mobile diagnostic instruments with recurring single-use test cards to hospitals, emergency services, and NHS-type healthcare facilities. Key collaborations include a UK clinical and manufacturing consortium (Guy's and St Thomas' NHS Foundation Trust, King's College London, Lightning Health, and G&H | ITL) supported by a SEK 17 million (£1.26 million) NIHR i4i Product Development Award, plus a 2026 collaboration with BRAINBox Solutions extending the platform into traumatic brain injury and neurodegenerative disease diagnostics.
Prolight Diagnostics firmographics
Firmographics- Name
- Prolight Diagnostics
- Legal name
- Prolight Diagnostics AB
- Website
- https://prolightdiagnostics.se
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Prolight Diagnostics AB is a Swedish pre-commercial medical diagnostics company developing the Psyros® digital point-of-care platform, which uses proprietary single molecule counting to deliver ultra-sensitive biomarker results from a drop of blood in under 10 minutes for emergency and acute care settings.
- Ownership category
- akta.pro rank
Prolight Diagnostics industry classification
Industry- Product category
- Point-of-Care Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer) (HLAHAOAC)
- akta.pro secondary industries
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where Prolight Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Prolight Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Point-of-Care Diagnostic Instruments and Test Cards: Prolight Diagnostics generates revenue through the sale of small mobile diagnostic instruments with single-use test cards for point-of-care testing. Healthcare providers purchase instruments and ongoing test cards for patient testing in ambulances, emergency departments, healthcare centers, and nursing homes.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Prolight Diagnostics product offering
Product offeringCore offering
Prolight Diagnostics AB develops small mobile point-of-care (POC) / patient-near analysis (PNA) diagnostic instruments with single-use test cards that perform in-vitro diagnostic (IVD) tests from a drop of blood outside traditional hospital laboratories. The flagship Psyros® platform uses proprietary digital single molecule counting technology to deliver reliable results in 10 minutes or less, enabling ultra-sensitive biomarker detection such as high-sensitivity troponin for acute cardiac events. The MicroFlex system complements the portfolio with disposable test cards for IVD testing in ambulances, emergency departments, healthcare centers, and nursing homes.
Product overview
Prolight Diagnostics AB develops a portfolio of point-of-care (POC) diagnostic systems consisting of the Psyros® platform and MicroFlex product line. Psyros® is a digital POC platform that utilizes proprietary single molecule counting technology, representing a paradigm shift from traditional analog POC systems. MicroFlex provides additional POC testing capability. Both products are small mobile instruments with single-use test cards that perform IVD tests from a blood drop, designed for use in ambulances, emergency departments, healthcare centers, and nursing homes.
Differentiator
Problem solved
Functional benefit
Brands
- Psyros: Digital point-of-care diagnostic platform using single molecule counting technology for rapid detection of acute health events including heart attack detection.
- Psyros®
- MicroFlex
Products and services
- Psyros® Digital point-of-care diagnostic platform using proprietary single molecule counting technology to deliver reliable test results in 10 minutes or less from a single drop of blood, with multiplex biomarker capability. Designed for ultra-sensitive detection of biomarkers such as high-sensitivity troponin for acute heart attack detection in ambulances, emergency departments, healthcare centers, and nursing homes.
Quantifiable outcome
- 10 minutes or less for reliable diagnostic results at point of care
- +2 more outcomes
Companies that use Prolight Diagnostics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Prolight Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Prolight Diagnostics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- G&H | ITLcoreDevelopment and manufacturing partner for the Psyros point-of-care diagnostic instrument. G&H collaborated on achieving formal design freeze with improvements in mechanical and optical stability to support scalable manufacturing and reliable operation in demanding clinical environments. Now proceeding with pilot unit production for system verification and validation.
- BRAINBox SolutionsminorCollaboration announced for point-of-care testing, aiming to create precision diagnostic tools for traumatic brain injury (TBI) and neurodegenerative diseases, combining Prolight's Psyros technology with BRAINBox's diagnostic programs.
- Guy's and St Thomas' NHS Foundation TrustcoreCollaboration with Prolight Diagnostics on the NIHR i4i Product Development Award for Psyros platform development. The NHS Foundation Trust provides clinical expertise and hosts pre-validation studies at St Thomas' Hospital before clinical validation in 2025.
- King's College LondoncoreAcademic partner in the NIHR i4i funded collaboration contributing research expertise and academic rigor to the Psyros platform development alongside NHS and industry partners.
- Lightning HealthcoreIndustry partner in the NIHR i4i Product Development Award collaboration supporting product development, pilot manufacturing, clinical studies, and technical submissions for the Psyros platform.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Prolight Diagnostics competitors and assessment
Company assessmentBroad incumbents
- QuidelOrtho: QuidelOrtho is a large diagnostics company offering the Triage family of point-of-care cardiovascular tests including high-sensitivity troponin assays. It is a broad incumbent competing with Prolight's Psyros in the cardiac POC market and serves similar emergency and acute care customers.
- Abbott: Abbott offers the i-STAT system, one of the most widely deployed point-of-care platforms globally, with troponin and other cardiac assays used in EDs and ambulances. It is a broad incumbent in cardiac POC testing and a direct competitor to Prolight's Psyros platform.
- Roche Diagnostics: Roche offers the cobas h232 POC system and central lab troponin assays used in cardiac diagnostics. It is a broad incumbent with both POC and central laboratory offerings overlapping Prolight's intended use cases in acute care.
- Siemens Healthineers: Siemens Healthineers offers the Atellica VTLI patient-side blood analyzer and broader cardiac diagnostics portfolio. As a broad incumbent in clinical diagnostics and POC testing, it competes with Prolight in the acute care and ED segments targeted by Psyros.
- Philips (BioTelemetry / Minicare): Philips developed the Minicare POC platform aimed at acute care diagnostics including cardiac biomarkers. As a broad incumbent with established hospital relationships and patient monitoring offerings, it is comparable to Prolight's broader POC ambitions beyond just cardiac.
- BioMérieux: BioMérieux is a global in vitro diagnostics company offering a broad portfolio including immunoassay platforms used for cardiac and critical care diagnostics. It is a broad incumbent in clinical diagnostics with adjacent technology and customer overlap with Prolight's POC ambitions.
Direct peers
- Response Biomedical: Response Biomedical develops rapid point-of-care cardiovascular tests including troponin assays on its RAMP platform. It is a direct peer to Prolight given its focus on rapid cardiac biomarker POC testing in emergency and acute care settings.
- Mesa Labs: Mesa Labs offers the QC product line and has historically been involved in rapid cardiac diagnostics including troponin POC testing through its acquisition of several diagnostic platforms. It is a direct peer in cardiac point-of-care diagnostics serving similar customer workflows.
Emerging players
- Boditech Med: Boditech Med manufactures point-of-care immunoassay analyzers and cardiac biomarker tests including troponin, primarily serving Asian and emerging markets. It is an emerging player with overlapping cardiac POC capabilities to Prolight's Psyros.
- ET Healthcare (Poclight): Poclight develops single-use POC diagnostic devices with focus on rapid biomarker testing. It is an emerging player with overlapping POC technology ambitions and similar target customers to Prolight in acute and emergency settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Prolight Diagnostics social profiles
Digital presenceProlight Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prolight Diagnostics leadership team
Management profileNumber of profiles
Prolight Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prolight Diagnostics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prolight Diagnostics
What does Prolight Diagnostics do?
Prolight Diagnostics AB develops small mobile point-of-care (POC) / patient-near analysis (PNA) diagnostic instruments with single-use test cards that perform in-vitro diagnostic (IVD) tests from a drop of blood outside traditional hospital laboratories. The flagship Psyros® platform uses proprietary digital single molecule counting technology to deliver reliable results in 10 minutes or less, enabling ultra-sensitive biomarker detection such as high-sensitivity troponin for acute cardiac events. The MicroFlex system complements the portfolio with disposable test cards for IVD testing in ambulances, emergency departments, healthcare centers, and nursing homes.
Is Prolight Diagnostics a public or private company?
Prolight Diagnostics is a private company. It is classified as unknown and is currently operating.
When was Prolight Diagnostics founded?
Prolight Diagnostics was founded in 1999. It employs 11 to 50 people.
Where is Prolight Diagnostics based?
Prolight Diagnostics is headquartered in Lund, Sweden, in the Europe region.
How does Prolight Diagnostics make money?
One revenue line is on record: point-of-Care Diagnostic Instruments and Test Cards.
Who are Prolight Diagnostics's main competitors?
Broad incumbents on record are QuidelOrtho, Abbott, Roche Diagnostics, Siemens Healthineers, Philips (BioTelemetry / Minicare) and BioMérieux. Direct peers are Response Biomedical and Mesa Labs. Emerging players are Boditech Med and ET Healthcare (Poclight).
Does Prolight Diagnostics have an API?
No public API is recorded for Prolight Diagnostics.
What industry is Prolight Diagnostics in?
Prolight Diagnostics's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAOAC, Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 334510 and its SIC code is 3841.